<DOC>
	<DOC>NCT01797419</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of GS-5806 in hospitalized infants with RSV.</brief_summary>
	<brief_title>Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>&lt;24 months of age Diagnosis of Respiratory Syncytial Virus (RSV) within 48 hours of screening Chronic or congenital heart disease Required ventilation or admission to any pediatric Intensive Care Unit Inadequate organ function</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Respiratory</keyword>
	<keyword>Syncytial</keyword>
	<keyword>Virus</keyword>
	<keyword>RSV</keyword>
</DOC>